Pini Orbach, PhD, is the Head of the Pharma Division of Arkin Holdings and Board Member at several of its pharmaceutical companies, including UroGen Pharma and Quiet Therapeutics, where he shares his extensive hands-on drug development and business experience. Prior to the merger with Ayala Pharmaceuticals, Pini was Chairman of Biosight. He has worked with US based companies such as, Arisaph Pharmaceuticals and Epix Pharmaceuticals, as well as Israeli based companies such as, cCAM BioTherapeutics a cancer immunotherapy company sold to Merck in 2015 for $605 million. Pini holds a PhD from the University of Florida and was a postdoctoral fellow at Massachusetts General Hospital’s Harvard Medical School.